The listings featured on this site are from companies from which this site receives compensation. This influences where, how and in what order such listings appear on this site. Advertising Disclosure

Compare Zepbound® Providers & Affordable Alternatives

Compare telehealth providers that prescribe Zepbound® — including how dose-level pricing, refill timing, and clinician access differ between programs.

Last Updated: Jun 2026


What’s on this page?

  1. Top Zepbound® telehealth providers of 2026 (above)
  2. What Zepbound® is
  3. Zepbound®, Mounjaro®, and compounded tirzepatide
  4. What the trial evidence shows
  5. What treatment costs to plan for
  6. Safety warnings before you start
  7. Picking a Zepbound® provider

What is Zepbound®?

Zepbound® is the brand of tirzepatide the FDA approved in November 2023 for chronic weight management. It is a once-weekly injection for adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition, prescribed together with a reduced-calorie diet and increased physical activity.

What sets it apart mechanically: per the FDA, tirzepatide activates receptors for two intestinal hormones — GLP-1 and GIP — that together reduce appetite and food intake. Treatment is titrated upward over 4 to 20 weeks to a maintenance dose of 5, 10, or 15 mg weekly.


Zepbound®, Mounjaro®, and compounded tirzepatide — what's the difference?

All three contain or claim to contain tirzepatide, but they are not interchangeable on paper:

  • Zepbound® is FDA-approved for chronic weight management.
  • Mounjaro® is the same active ingredient approved for type 2 diabetes — the FDA notes the two should not be used together.
  • Compounded tirzepatide is pharmacy-prepared and not an FDA-approved product; if a telehealth provider offers it, ask which pharmacy fills it and what oversight is included.

What does the trial evidence show?

Zepbound®'s approval rests on two 72-week placebo-controlled trials totaling about 3,500 participants. In the larger trial of adults without diabetes — average starting weight 231 pounds — people on the highest dose lost an average of 18% of body weight relative to placebo, per the FDA. The SURMOUNT-1 results behind that figure: 15.0%, 19.5%, and 20.9% average reductions on 5, 10, and 15 mg respectively, versus 3.1% on placebo.

Extended follow-up also recorded weight regain after participants stopped treatment. Plan for the maintenance phase before you start, not after.


What treatment costs should you plan for?

Zepbound® pricing varies by dose, pharmacy, insurance, and manufacturer savings programs — and telehealth programs layer their own membership or visit fees on top. The advertised first-month price is rarely the steady-state price.

Before committing, get three numbers in writing: the monthly cost at your likely maintenance dose (not just the starting dose), what the program charges for provider visits and follow-ups, and what happens to billing if you pause treatment. A provider that cannot answer those plainly is telling you something.


Safety warnings before you start

From the FDA's approval announcement: Zepbound® should not be used by people with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2. It has not been studied in people with a history of pancreatitis or severe gastrointestinal disease, and it carries warnings involving the pancreas, gallbladder, kidneys, blood sugar, diabetic retinopathy, and suicidal behavior or thinking.

Common side effects include nausea, diarrhea, vomiting, constipation, abdominal discomfort, injection-site reactions, fatigue, and reflux. A legitimate telehealth provider screens for all of this in the intake — treat a thin questionnaire as a red flag.


How should you pick a Zepbound® provider?

Use the chart above to shortlist, then compare where programs actually differ: brand-name versus compounded supply, dose-level pricing, refill reliability during the titration months, and whether you can message a clinician when side effects show up at a dose increase.

If you have insurance, check coverage for brand-name Zepbound® before paying cash anywhere — some programs will run that check for you at no cost.

Ready to compare Zepbound® providers?

Shortlist two or three companies above, read their full reviews, and confirm maintenance-dose pricing, pharmacy source, and clinician access before your online visit.

Sources used for medical context

  1. FDA Zepbound approval announcement (2023) for indication, mechanism, trial summary, titration, and warnings.
  2. SURMOUNT-1 trial summary (ACC) for dose-level outcomes and post-treatment follow-up.

How We Rank

Learn more about how comparetreatments.com rankings are determined.

Frequently Asked Questions (FAQ)

No. Zepbound® is a prescription medication. Telehealth providers can prescribe it after a licensed clinician reviews your online intake and confirms you meet the criteria — obesity, or overweight with a weight-related condition, per the FDA indication. Anyone selling it without medical review should be avoided.
In the 72-week SURMOUNT-1 trial, average reductions were 15.0% to 20.9% of body weight depending on dose, versus 3.1% for placebo, with lifestyle intervention included. The FDA cites an 18% average loss versus placebo at the highest dose in adults without diabetes. Individual results vary.
No. Compounded versions are pharmacy-prepared and are not FDA-approved products, which means they sit outside the quality controls of the branded supply chain. If a program offers compounded tirzepatide, confirm the pharmacy source, the exact contents, and the clinical oversight before paying.
The FDA lists nausea, diarrhea, vomiting, constipation, abdominal discomfort, injection-site reactions, fatigue, allergic reactions, burping, hair loss, and reflux. Most gastrointestinal effects cluster around dose increases. Contact your care team about persistent or severe symptoms.
Coverage varies widely by plan, and weight-management medications are excluded from some policies entirely. Before paying cash, ask your insurer directly or use a telehealth program that runs a coverage check first — several companies in our chart offer that at no cost.